S&P 500   3,903.25 (-0.52%)
DOW   31,244.07 (-0.78%)
QQQ   290.32 (-0.28%)
AAPL   137.39 (-2.44%)
MSFT   253.27 (-0.32%)
FB   191.92 (-0.17%)
GOOGL   2,211.56 (-1.18%)
AMZN   2,157.13 (+0.69%)
TSLA   711.53 (+0.24%)
NVDA   172.47 (+1.82%)
BABA   88.18 (+1.00%)
NIO   16.68 (+5.37%)
AMD   97.82 (+1.60%)
CGC   5.87 (+5.01%)
MU   69.50 (-2.18%)
T   20.12 (-0.54%)
GE   75.52 (+0.43%)
F   12.90 (+0.94%)
DIS   103.29 (-0.97%)
AMC   12.77 (+0.08%)
PFE   50.27 (-0.26%)
PYPL   81.28 (+5.31%)
NFLX   184.51 (+4.13%)
S&P 500   3,903.25 (-0.52%)
DOW   31,244.07 (-0.78%)
QQQ   290.32 (-0.28%)
AAPL   137.39 (-2.44%)
MSFT   253.27 (-0.32%)
FB   191.92 (-0.17%)
GOOGL   2,211.56 (-1.18%)
AMZN   2,157.13 (+0.69%)
TSLA   711.53 (+0.24%)
NVDA   172.47 (+1.82%)
BABA   88.18 (+1.00%)
NIO   16.68 (+5.37%)
AMD   97.82 (+1.60%)
CGC   5.87 (+5.01%)
MU   69.50 (-2.18%)
T   20.12 (-0.54%)
GE   75.52 (+0.43%)
F   12.90 (+0.94%)
DIS   103.29 (-0.97%)
AMC   12.77 (+0.08%)
PFE   50.27 (-0.26%)
PYPL   81.28 (+5.31%)
NFLX   184.51 (+4.13%)
S&P 500   3,903.25 (-0.52%)
DOW   31,244.07 (-0.78%)
QQQ   290.32 (-0.28%)
AAPL   137.39 (-2.44%)
MSFT   253.27 (-0.32%)
FB   191.92 (-0.17%)
GOOGL   2,211.56 (-1.18%)
AMZN   2,157.13 (+0.69%)
TSLA   711.53 (+0.24%)
NVDA   172.47 (+1.82%)
BABA   88.18 (+1.00%)
NIO   16.68 (+5.37%)
AMD   97.82 (+1.60%)
CGC   5.87 (+5.01%)
MU   69.50 (-2.18%)
T   20.12 (-0.54%)
GE   75.52 (+0.43%)
F   12.90 (+0.94%)
DIS   103.29 (-0.97%)
AMC   12.77 (+0.08%)
PFE   50.27 (-0.26%)
PYPL   81.28 (+5.31%)
NFLX   184.51 (+4.13%)
S&P 500   3,903.25 (-0.52%)
DOW   31,244.07 (-0.78%)
QQQ   290.32 (-0.28%)
AAPL   137.39 (-2.44%)
MSFT   253.27 (-0.32%)
FB   191.92 (-0.17%)
GOOGL   2,211.56 (-1.18%)
AMZN   2,157.13 (+0.69%)
TSLA   711.53 (+0.24%)
NVDA   172.47 (+1.82%)
BABA   88.18 (+1.00%)
NIO   16.68 (+5.37%)
AMD   97.82 (+1.60%)
CGC   5.87 (+5.01%)
MU   69.50 (-2.18%)
T   20.12 (-0.54%)
GE   75.52 (+0.43%)
F   12.90 (+0.94%)
DIS   103.29 (-0.97%)
AMC   12.77 (+0.08%)
PFE   50.27 (-0.26%)
PYPL   81.28 (+5.31%)
NFLX   184.51 (+4.13%)
NASDAQ:LNTH

Lantheus (LNTH) Stock Forecast, Price & News

$63.83
+0.97 (+1.54%)
(As of 05/19/2022 01:19 PM ET)
Add
Compare
Today's Range
$62.24
$64.84
50-Day Range
$49.87
$66.89
52-Week Range
$19.30
$69.74
Volume
19,820 shs
Average Volume
1.34 million shs
Market Capitalization
$4.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.76
30 days | 90 days | 365 days | Advanced Chart
Receive LNTH News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

Lantheus logo

About Lantheus

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Headlines

Lantheus Hosts Inaugural Investor Day
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LNTH
Employees
612
Year Founded
N/A

Sales & Book Value

Annual Sales
$425.21 million
Cash Flow
$1.22 per share
Book Value
$7.52 per share

Profitability

Net Income
$-71.28 million
Pretax Margin
-5.81%

Debt

Price-To-Earnings

Miscellaneous

Free Float
67,536,000
Market Cap
$4.38 billion
Optionable
Optionable

Company Calendar

Last Earnings
4/29/2022
Today
5/19/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.45 out of 5 stars

Medical Sector

171st out of 1,418 stocks

Diagnostic Substances Industry

1st out of 27 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -













Lantheus (NASDAQ:LNTH) Frequently Asked Questions

Is Lantheus a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Lantheus stock.
View analyst ratings for Lantheus
or view top-rated stocks.

When is Lantheus' next earnings date?

Lantheus is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Lantheus
.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its quarterly earnings results on Friday, April, 29th. The medical equipment provider reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.46 by $0.51. The medical equipment provider earned $208.90 million during the quarter, compared to analysts' expectations of $165.30 million. Lantheus had a positive trailing twelve-month return on equity of 19.83% and a negative net margin of 6.89%. The business's quarterly revenue was up 125.8% on a year-over-year basis. During the same period last year, the firm earned $0.05 EPS.
View Lantheus' earnings history
.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $2.90-$3.15 for the period, compared to the consensus earnings per share estimate of $2.05. The company issued revenue guidance of $800.00 million-$835.00 million, compared to the consensus revenue estimate of $711.56 million.

What price target have analysts set for LNTH?

3 Wall Street analysts have issued 12 month target prices for Lantheus' stock. Their forecasts range from $75.00 to $94.00. On average, they expect Lantheus' stock price to reach $86.67 in the next twelve months. This suggests a possible upside of 35.8% from the stock's current price.
View analysts' price targets for Lantheus
or view top-rated stocks among Wall Street analysts.

Who are Lantheus' key executives?
Lantheus' management team includes the following people:
What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus CEO Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among Lantheus' employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lantheus own?
When did Lantheus IPO?

(LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.54%), Vanguard Group Inc. (8.37%), State Street Corp (3.48%), Dimensional Fund Advisors LP (2.42%), Lord Abbett & CO. LLC (1.89%) and William Blair Investment Management LLC (1.77%). Company insiders that own Lantheus stock include Andrea Sabens, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends for Lantheus
.

Which institutional investors are selling Lantheus stock?

LNTH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, William Blair Investment Management LLC, Russell Investments Group Ltd., Polar Asset Management Partners Inc., Peregrine Capital Management LLC, Reinhart Partners Inc., Velan Capital Investment Management LP, and Next Century Growth Investors LLC. Company insiders that have sold Lantheus company stock in the last year include Andrea Sabens, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, John J Bolla, Mary Anne Heino, Paul Blanchfield, and Robert J Jr Marshall.
View insider buying and selling activity for Lantheus
or view top insider-selling stocks.

Which institutional investors are buying Lantheus stock?

LNTH stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Lord Abbett & CO. LLC, Fuller & Thaler Asset Management Inc., Renaissance Technologies LLC, Hood River Capital Management LLC, Penn Capital Management Company LLC, Assenagon Asset Management S.A., and Arrowstreet Capital Limited Partnership.
View insider buying and selling activity for Lantheus
or or view top insider-buying stocks.

How do I buy shares of Lantheus?

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $63.83.

How much money does Lantheus make?

Lantheus has a market capitalization of $4.38 billion and generates $425.21 million in revenue each year. The medical equipment provider earns $-71.28 million in net income (profit) each year or ($0.57) on an earnings per share basis.

How many employees does Lantheus have?

Lantheus employs 612 workers across the globe.

What is Lantheus' official website?

The official website for Lantheus is www.lantheus.com.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at (978) 671-8001, via email at [email protected], or via fax at 978-671-8860.

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.